Healthy Adult ParticipantsNCT07684534
Effect of the Ultrasound-guided Percutaneous Neuromodulation on the Mean Velocity in Crossfit Practitioners.
A study testing ultrasound-guided percutaneous neuromodulation in people with Healthy Adult Participants and Crossfit, run by CEU San Pablo University at 1 site in Spain.
Trial summary
This randomized controlled blinded clinical trial aims to evaluate the effect of ultrasound-guided percutaneous neuromodulation (US-guided PNM) targeting the innervation of the transversus abdominis muscle on squat performance in CrossFit practitioners. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Adult Participants, Crossfit
- What is being tested?
- ultrasound-guided percutaneous neuromodulation
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 42 participants
- Where
- 1 siteSpain
- Study dates
- 8 Jul 2026to 1 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age between 18 and 60 years
- At least 1 year of CrossFit training experience
- Training frequency between 2 and 6 sessions per week
Who cannot join
- Belonephobia (fear of needles)
- Presence of cardiac conditions or implanted cardiac devices (e.g., pacemaker)
- Pregnancy
- Active oncological process
- Skin conditions or lesions in the intervention area
- Neurological or neurosensory disorders
Show all 16Show fewer
- Epilepsy
- Current febrile condition
- Recent use of antibiotics
- Treatment with anticoagulant medication
- Use of medications that may affect physical performance
- Autoimmune diseases or use of immunosuppressive therapy
- Active lumbar or abdominal pathology
- Recent lumbar surgery or operations related to the intervention area
- Active musculoskeletal injury or pain affecting squat technique or -performance
- Undiagnosed pain affecting execution of the sporting movement.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Fisiosport premium SL
Murcia, Murcia, 30007
Francisco Navarro Pastor, Physiotherapist, +34 685536102, navarropastorpaco@gmail.com
About this study
Official title: Effect of Ultrasound-guided Percutaneous Neuromodulation of the Transversus Abdominis on the Force-Velocity Profile During the Squat Performance in Crossfit Practitioners.
This randomized controlled blinded clinical trial aims to evaluate the effect of ultrasound-guided percutaneous neuromodulation (US-guided PNM) targeting the innervation of the transversus abdominis muscle on squat performance in CrossFit practitioners.
The transversus abdominis is a deep trunk muscle that contributes to lumbopelvic stability and force transmission during functional and athletic movements. Previous research suggests that improving neuromuscular activation of the trunk musculature may enhance movement efficiency and performance during resistance exercises. Ultrasound-guided percutaneous neuromodulation is a minimally invasive technique that applies electrical stimulation through a needle placed close to a peripheral nerve under ultrasound guidance, with the aim of modulating neuromuscular function.
Read more
Healthy male and female CrossFit practitioners aged 18 to 60 years, with at least one year of training experience, will participate in the study. Participants will undergo an initial ultrasound assessment of transversus abdominis activation to classify and distribute the sample into groups. In a second session, mean velocity, mean propulsive velocity, and velocity loss during squat performance will be assessed using a linear velocity transducer. Participants will perform 3 sets of 2 repetitions of the squat exercise at 80% of their one-repetition maximum (1RM).
Following baseline assessment, participants will be randomly assigned to either an experimental group receiving ultrasound-guided percutaneous neuromodulation of the iliohypogastric and ilioinguinal nerves, or a sham group receiving needle insertion without electrical stimulation. The intervention will consist of a TENS-type current applied at 10 Hz for 10 cycles of 10 seconds. Squat performance variables will be reassessed immediately after the intervention.
The purpose of this study is to determine whether US-guided percutaneous neuromodulation can acutely improve squat performance in trained CrossFit practitioners. The study hypothesis is that participants receiving active neuromodulation will demonstrate greater improvements in squat execution velocity and lower velocity loss compared with participants receiving the sham intervention.
Read the detailed description
CrossFit training requires the integration of strength, power, trunk stability, and efficient force transmission during complex multi-joint movements. The back squat is one of the most frequently used exercises in CrossFit and is commonly applied to assess lower-limb performance through force-velocity profiling. Variables such as mean velocity, mean propulsive velocity, and velocity loss between sets provide relevant information regarding neuromuscular performance and fatigue resistance.
The transversus abdominis is a deep abdominal muscle involved in trunk stabilization and lumbopelvic control. Adequate activation of this muscle may contribute to improved force transmission between the lower and upper extremities during strength exercises. Ultrasound-guided percutaneous neuromodulation (UGPNM) is an invasive physiotherapy technique that delivers electrical stimulation through a needle placed near a peripheral nerve under ultrasound guidance. This intervention has been proposed as a method to modulate neuromuscular function and potentially enhance motor performance.
Despite the increasing use of ultrasound-guided percutaneous neuromodulation in clinical and sports settings, evidence regarding its immediate effects on sport performance variables remains limited. In particular, the influence of neuromodulation targeting the innervation of the transversus abdominis on force-velocity profile characteristics during the squat has not been thoroughly investigated.
The objective of this randomized controlled trial is to evaluate the immediate effects of ultrasound-guided percutaneous neuromodulation of the nerves supplying the transversus abdominis on mean velocity during the back squat in CrossFit practitioners. Secondary outcomes include mean propulsive velocity, fatigue resistance assessed through velocity loss between sets, perceived exertion, and potential differences in response according to baseline transversus abdominis activation capacity.
A total of 42 healthy CrossFit practitioners, both male and female, aged 18 to 60 years with at least one year of training experience, will be recruited. During baseline assessment, participants will undergo ultrasound evaluation of the transversus abdominis muscle at rest and during voluntary contraction. Muscle thickness will be measured in both conditions, and the percentage of activation will be calculated based on the relative change in thickness. Participants will then be classified into higher and lower activation subgroups according to the median value of transversus abdominis activation.
Following this classification, participants will be randomly allocated to either the experimental or sham group using block randomization performed with R statistical software, ensuring balanced distribution of activation levels between groups.
A blinded randomized controlled design with third-party outcome assessment will be used. Outcome assessments will be performed by a blinded evaluator responsible for ultrasound measurements of transversus abdominis thickness and for collecting squat performance variables obtained via a linear velocity transducer. The evaluator will not be involved in the randomization process and will remain unaware of group allocation throughout the study.
A separate clinician, not involved in outcome assessment, will administer either the active ultrasound-guided percutaneous neuromodulation intervention or the sham procedure. Participants will remain blinded to treatment allocation throughout the study.
The baseline performance assessment will include squat testing using a linear velocity transducer. Participants will perform three sets of two repetitions at 80% of their individual one-repetition maximum (1RM), following a standardized warm-up. Mean velocity, mean propulsive velocity, velocity loss, and rating of perceived exertion will be recorded.
The experimental intervention will consist of ultrasound-guided percutaneous neuromodulation applied to the iliohypogastric and ilioinguinal nerves using electrical stimulation at 10 Hz in 10-second cycles. The sham condition will involve identical needle insertion without electrical stimulation. Immediately after the intervention, all performance variables will be reassessed under identical testing conditions.
This study aims to determine whether ultrasound-guided percutaneous neuromodulation can produce immediate improvements in squat performance variables and whether baseline transversus abdominis activation capacity influences the response to the intervention.
- Conditions
- Healthy Adult Participants, Crossfit
- Being tested
- ultrasound-guided percutaneous neuromodulation, ultrasound-guided percutaneous neuromodulation (sham)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ultrasound-guided percutaneous neuromodulationOther
The intervention will be applied using ultrasound-guided percutaneous neuromodulation of the iliohypogastric and ilioinguinal nerves. The procedure will be performed under ultrasound guidance using a sterile percutaneous needle. In the experimental group, electrical stimulation will be delivered through the needle at a frequency of 10 Hz in 10-second cycles. Stimulation intensity will be adjusted according to participant tolerance, without exceeding the pain threshold.
ultrasound-guided percutaneous neuromodulation (sham)Other
The sham intervention consists of an ultrasound-guided percutaneous needle insertion performed in the same anatomical region as the experimental procedure (iliohypogastric and ilioinguinal nerves), using identical positioning and procedural setup. No electrical stimulation is delivered through the needle at any point during the procedure. The duration and handling of the procedure are matched to the experimental condition to ensure participant blinding.
| Study group | Role | What they receive |
|---|---|---|
| ultrasound-guided percutaneous neuromodulation | Experimental | The patients will receive ultrasound-guided percutaneous neuromodulation of the iliohypogastric and ilioinguinal nerves using electrical stimulation at 10 Hz in 10-second cycles. Receives: Other: ultrasound-guided percutaneous neuromodulation |
| Ultrasound-guided percutaneous neuromodulation (sham) | Sham comparator | The patients will receive a sham ultrasound-guided percutaneous neuromodulation procedure involving identical needle insertion under ultrasound guidance without electrical stimulation Receives: Other: ultrasound-guided percutaneous neuromodulation (sham) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Velocity during Back Squat (Linear Velocity Transducer)
Mean velocity will be measured using a linear position transducer attached to the barbell during the back squat exercise. This device records bar displacement over time and allows calculation of bar velocity during the concentric phase of each repetition. The mean velocity of each repetition will be recorded, and the average across repetitions and sets will be used for analysis.
Measured: Baseline assessment (pre-intervention) and immediately after the intervention (post-intervention, same session).
Secondary outcomes (4)
Mean Propulsive Velocity during Back Squat (Linear Velocity Transducer)
Mean propulsive velocity will be measured using a linear position transducer attached to the barbell during the back squat exercise. Mean propulsive velocity corresponds to the average bar velocity during the propulsive phase of the concentric movement, from the start of the upward movement until bar acceleration falls below gravitational acceleration. The average value across repetitions and sets will be used for analysis.
Measured: Baseline assessment (pre-intervention) and immediately after the intervention (post-intervention, same session).
Velocity Loss Between Sets during Back Squat (Linear Velocity Transducer)
Velocity loss between sets will be calculated from the mean velocity recorded by the linear position transducer during the back squat exercise. This variable will be expressed as the percentage reduction in movement velocity between sets and will be used as an indicator of fatigue resistance.
Measured: Baseline assessment (pre-intervention) and immediately after the intervention (post-intervention, same session).
Rating of Perceived Exertion (RPE)
Perceived exertion during the back squat exercise will be assessed using a rating of perceived exertion (RPE) scale. Participants will rate the perceived intensity of the exercise after completing the squat protocol. Higher scores indicate greater perceived effort.
Measured: Baseline assessment (pre-intervention), immediately after the intervention (post-intervention, same session), 1 week after the intervention, and 2 weeks after the intervention.
Activation of the transverse abdominal muscle
The investigators will measure the resting and activation thicknesses and will calculate the activation ratio.
Measured: Baseline assessment (pre-intervention) and immediately after the intervention (post-intervention, same session).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2026
- Study start8 Jul 2026
- Primary completion1 Oct 2026 (estimated)
- Study completion1 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy Adult ParticipantsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 42 participants (estimated)
Sponsor and investigators
- Lead sponsor
- CEU San Pablo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Paco Navarro Pastor, CEU San Pablo University
- Investigators
- Francisco N Navarro Pastor, Physiotherapist, Principal investigator, CEU San Pablo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07684534
- Sponsor's protocol ID
- CdEi94
- Status last verified
- Jul 2026
- First submitted
- 29 Jun 2026
- Last updated
- 10 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized study data will be made available to other researchers upon reasonable request and following consultation with the principal investigator
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Ultrasound-guided Percutaneous Neuromodulation of the Transversus Abdominis on the Force-Velocity Profile During the Squat Performance in Crossfit Practitioners.
- ClinicalTrials.gov ID
- NCT07684534
- Acronym / sponsor ID
- CdEi94
- Conditions
- Healthy Adult Participants, Crossfit
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 42 participants (estimated)
- Lead sponsor
- CEU San Pablo UniversityUniversity, hospital or other
- Study start
- 8 Jul 2026 (actual)
- Primary completion
- 1 Oct 2026 (estimated)
- Study completion
- 1 Nov 2026 (estimated)
- First posted
- 6 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled blinded clinical trial aims to evaluate the effect of ultrasound-guided percutaneous neuromodulation (US-guided PNM) targeting the innervation of the transversus abdominis muscle on squat performance in CrossFit practitioners.
The transversus abdominis is a deep trunk muscle that contributes to lumbopelvic stability and force transmission during functional and athletic movements. Previous research suggests that improving neuromuscular activation of the trunk musculature may enhance movement efficiency and performance during resistance exercises. Ultrasound-guided percutaneous neuromodulation is a minimally invasive technique that applies electrical stimulation through a needle placed close to a peripheral nerve under ultrasound guidance, with the aim of modulating neuromuscular function.
Healthy male and female CrossFit practitioners aged 18 to 60 years, with at least one year of training experience, will participate in the study. Participants will undergo an initial ultrasound assessment of transversus abdominis activation to classify and distribute the sample into groups. In a second session, mean velocity, mean propulsive velocity, and velocity loss during squat performance will be assessed using a linear velocity transducer. Participants will perform 3 sets of 2 repetitions of the squat exercise at 80% of their one-repetition maximum (1RM).
Following baseline assessment, participants will be randomly assigned to either an experimental group receiving ultrasound-guided percutaneous neuromodulation of the iliohypogastric and ilioinguinal nerves, or a sham group receiving needle insertion without electrical stimulation. The intervention will consist of a TENS-type current applied at 10 Hz for 10 cycles of 10 seconds. Squat performance variables will be reassessed immediately after the intervention.
The purpose of this study is to determine whether US-guided percutaneous neuromodulation can acutely improve squat performance in trained CrossFit practitioners. The study hypothesis is that participants receiving active neuromodulation will demonstrate greater improvements in squat execution velocity and lower velocity loss compared with participants receiving the sham intervention.
Detailed description
CrossFit training requires the integration of strength, power, trunk stability, and efficient force transmission during complex multi-joint movements. The back squat is one of the most frequently used exercises in CrossFit and is commonly applied to assess lower-limb performance through force-velocity profiling. Variables such as mean velocity, mean propulsive velocity, and velocity loss between sets provide relevant information regarding neuromuscular performance and fatigue resistance.
The transversus abdominis is a deep abdominal muscle involved in trunk stabilization and lumbopelvic control. Adequate activation of this muscle may contribute to improved force transmission between the lower and upper extremities during strength exercises. Ultrasound-guided percutaneous neuromodulation (UGPNM) is an invasive physiotherapy technique that delivers electrical stimulation through a needle placed near a peripheral nerve under ultrasound guidance. This intervention has been proposed as a method to modulate neuromuscular function and potentially enhance motor performance.
Despite the increasing use of ultrasound-guided percutaneous neuromodulation in clinical and sports settings, evidence regarding its immediate effects on sport performance variables remains limited. In particular, the influence of neuromodulation targeting the innervation of the transversus abdominis on force-velocity profile characteristics during the squat has not been thoroughly investigated.
The objective of this randomized controlled trial is to evaluate the immediate effects of ultrasound-guided percutaneous neuromodulation of the nerves supplying the transversus abdominis on mean velocity during the back squat in CrossFit practitioners. Secondary outcomes include mean propulsive velocity, fatigue resistance assessed through velocity loss between sets, perceived exertion, and potential differences in response according to baseline transversus abdominis activation capacity.
A total of 42 healthy CrossFit practitioners, both male and female, aged 18 to 60 years with at least one year of training experience, will be recruited. During baseline assessment, participants will undergo ultrasound evaluation of the transversus abdominis muscle at rest and during voluntary contraction. Muscle thickness will be measured in both conditions, and the percentage of activation will be calculated based on the relative change in thickness. Participants will then be classified into higher and lower activation subgroups according to the median value of transversus abdominis activation.
Following this classification, participants will be randomly allocated to either the experimental or sham group using block randomization performed with R statistical software, ensuring balanced distribution of activation levels between groups.
A blinded randomized controlled design with third-party outcome assessment will be used. Outcome assessments will be performed by a blinded evaluator responsible for ultrasound measurements of transversus abdominis thickness and for collecting squat performance variables obtained via a linear velocity transducer. The evaluator will not be involved in the randomization process and will remain unaware of group allocation throughout the study.
A separate clinician, not involved in outcome assessment, will administer either the active ultrasound-guided percutaneous neuromodulation intervention or the sham procedure. Participants will remain blinded to treatment allocation throughout the study.
The baseline performance assessment will include squat testing using a linear velocity transducer. Participants will perform three sets of two repetitions at 80% of their individual one-repetition maximum (1RM), following a standardized warm-up. Mean velocity, mean propulsive velocity, velocity loss, and rating of perceived exertion will be recorded.
The experimental intervention will consist of ultrasound-guided percutaneous neuromodulation applied to the iliohypogastric and ilioinguinal nerves using electrical stimulation at 10 Hz in 10-second cycles. The sham condition will involve identical needle insertion without electrical stimulation. Immediately after the intervention, all performance variables will be reassessed under identical testing conditions.
This study aims to determine whether ultrasound-guided percutaneous neuromodulation can produce immediate improvements in squat performance variables and whether baseline transversus abdominis activation capacity influences the response to the intervention.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ultrasound-guided percutaneous neuromodulation | Experimental | Other: ultrasound-guided percutaneous neuromodulationThe patients will receive ultrasound-guided percutaneous neuromodulation of the iliohypogastric and ilioinguinal nerves using electrical stimulation at 10 Hz in 10-second cycles. |
| Ultrasound-guided percutaneous neuromodulation (sham) | Sham comparator | Other: ultrasound-guided percutaneous neuromodulation (sham)The patients will receive a sham ultrasound-guided percutaneous neuromodulation procedure involving identical needle insertion under ultrasound guidance without electrical stimulation |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Age between 18 and 60 years
- At least 1 year of CrossFit training experience
- Training frequency between 2 and 6 sessions per week
Key exclusion criteria (16 listed)
- Belonephobia (fear of needles)
- Presence of cardiac conditions or implanted cardiac devices (e.g., pacemaker)
- Pregnancy
- Active oncological process
- Skin conditions or lesions in the intervention area
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ultrasound-guided percutaneous neuromodulationThe intervention will be applied using ultrasound-guided percutaneous neuromodulation of the iliohypogastric and ilioinguinal nerves. The procedure will be performed under ultrasound guidance using a sterile percutaneous needle. In the experimental group, electrical stimulation will be delivered through the needle at a frequency of 10 Hz in 10-second cycles. Stimulation intensity will be adjusted according to participant tolerance, without exceeding the pain threshold. | Other | ultrasound-guided percutaneous neuromodulation |
| ultrasound-guided percutaneous neuromodulation (sham)The sham intervention consists of an ultrasound-guided percutaneous needle insertion performed in the same anatomical region as the experimental procedure (iliohypogastric and ilioinguinal nerves), using identical positioning and procedural setup. No electrical stimulation is delivered through the needle at any point during the procedure. The duration and handling of the procedure are matched to the experimental condition to ensure participant blinding. | Other | Ultrasound-guided percutaneous neuromodulation (sham) |
Primary outcome
Mean Velocity during Back Squat (Linear Velocity Transducer)
Time frame: Baseline assessment (pre-intervention) and immediately after the intervention (post-intervention, same session).
Mean velocity will be measured using a linear position transducer attached to the barbell during the back squat exercise. This device records bar displacement over time and allows calculation of bar velocity during the concentric phase of each repetition. The mean velocity of each repetition will be recorded, and the average across repetitions and sets will be used for analysis.
4 secondary outcomes
Mean Propulsive Velocity during Back Squat (Linear Velocity Transducer)
Time frame: Baseline assessment (pre-intervention) and immediately after the intervention (post-intervention, same session).
Velocity Loss Between Sets during Back Squat (Linear Velocity Transducer)
Time frame: Baseline assessment (pre-intervention) and immediately after the intervention (post-intervention, same session).
Rating of Perceived Exertion (RPE)
Time frame: Baseline assessment (pre-intervention), immediately after the intervention (post-intervention, same session), 1 week after the intervention, and 2 weeks after the intervention.
Activation of the transverse abdominal muscle
Time frame: Baseline assessment (pre-intervention) and immediately after the intervention (post-intervention, same session).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2026.
- Individual participant dataSharing planned: Yes. Anonymized study data will be made available to other researchers upon reasonable request and following consultation with the principal investigator
Related trials for Healthy Adult Participants
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruiting
REM Enhancement Sleep Technology for Well-being, Emotion, and Life Lift
Healthy Adult Participants
RecruitingPhase 1
A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
Overweight and/or Obesity, Healthy Participants
RecruitingObservational study
Magnetic Field Maps With NV Application Kit MCG
Technical Feasibility and Performance of the Sensor System, Healthy Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Francisco N Navarro Pastor, Physiotherapist principal investigator
CEU San Pablo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ultrasound-guided percutaneous neuromodulation in people with Healthy Adult Participants and Crossfit, run by CEU San Pablo University at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Paco N Navarro Pastor, Physiotherapist (+34 685536102, navarropastorpaco@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Velocity during Back Squat (Linear Velocity Transducer) (time frame: Baseline assessment (pre-intervention) and immediately after the intervention (post-intervention, same session).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2026.